Current trends in the management of extra-abdominal desmoid tumours

被引：45

作者：

Papagelopoulos P.J. ^{[1
]}

Mavrogenis A.F. ^{[1
]}

Mitsiokapa E.A. ^{[2
]}

Papaparaskeva K.Th. ^{[3
]}

Galanis E.C. ^{[4
]}

Soucacos P.N. ^{[1
]}

机构：

[1] First Department of Orthopaedic Surgery, Athens University Medical School, Athens

[2] Department of Physical Medicine and Rehabilitation, Thriassion Hospital, Elefsis

[3] Department of Pathology, Hygeia Athens Medical Center, Athens

[4] Department of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN

来源：

World Journal of Surgical Oncology | / 4卷 / 1期

关键词：

Local Recurrence Rate; Meloxicam; Tretinoin; Desmoid Tumour; Goserelin;

D O I：

10.1186/1477-7819-4-21

中图分类号：

学科分类号：

摘要：

Extra-abdominal desmoid tumours are slow-growing, histologically benign tumours of fibroblastic origin with variable biologic behaviour. They are locally aggressive and invasive to surrounding anatomic structures. Magnetic resonance imaging is the modality of choice for the diagnosis and the evaluation of the tumours. Current management of desmoids involves a multidisciplinary approach. Wide margin surgical resection remains the main treatment modality for local control of the tumour. Amputation should not be the initial treatment, and function-preserving procedures should be the primary treatment goal. Adjuvant radiation therapy is recommended both for primary and recurrent lesions. Chemotherapy may be used for recurrent or unresectable disease. Overall local recurrence rates vary and depend on patient's age, tumour location and margins at resection. © 2006Papagelopoulos et al; licensee BioMed Central Ltd.

引用

共 72 条

[1]

Leithner A., Schnack B., Katterschafka T., Wiltschke C., Amann G., Windhager R., Kotz R., Zielinski C.C., Treatment of extra-abdominal desmoid tumours with interferon-alpha with or without tretinoin, J Surg Oncol, 73, pp. 21-25, (2000)

[2]

Spiegel D.A., Dormans J.P., Meyer J.S., Himelstein B., Mathur S., Asada N., Womer R.B., Aggressive fibromatosis from infancy to adolescence, J Pediatr Orthop, 19, pp. 776-784, (1999)

[3]

Stout A.P., Juvenile fibromatosis, Cancer, 7, pp. 953-971, (1954)

[4]

Reitamo J.J., Scheinin T.M., Hayry P., The desmoid syndrome: New aspects in the cause, pathogenesis and treatment of the desmoid tumour, Am J Surg, 151, pp. 230-237, (1986)

[5]

Lewis J.J., Boland P.J., Leung D.H.Y., Woodruff J.M., Brennan M.F., The Enigma of Desmoid Tumours, An Surg, 229, pp. 866-873, (1999)

[6]

Sherman N.E., Romsdahl M., Evans H., Zagars G., Oswald M.J., Desmoid tumours: A 20-year radiotherapy experience, Int J Radiat Oncol Biol Phys, 19, pp. 37-40, (1990)

[7]

Alman B.A., Li C., Pajerski M.E., Diaz-Cano S., Wolfe H.J., Increased beta catenin and somatic APC mutations in sporadic aggressive fibromatosis, Am J Pathol, 151, pp. 329-334, (1997)

[8]

Alman B.A., Pajerski M.E., Diaz-Cano S., Corboy K., Wolfe H.J., Aggressive fibromatosis (desmoid tumour) is a monoclonal disorder, Am J Surg Pathol, 68, pp. 194-200, (1996)

[9]

Li C., Bapat B., Alman B.A., Adenomatous polyposis coli gene mutation alters proliferation through its beta catenin regulatory function in aggressive fibromatosis (desmoid tumour), Am J Pathol, 153, pp. 709-714, (1998)

[10]

Muller E., Catsagnaro M., Yandel D.W., Wolfe H.J., Alman B.A., Molecular genetic and immunohistochemical analysis of the tumour suppressor genes Rb and p53 in palmar and aggressive fibromatosis, Am J Surg Pathol, 68, pp. 194-200, (1996)

← 1 2 3 4 5 6 7 8 →